Clinical Trials Browser

Advanced Bladder Cancer

NCT06104618 2026-06-08

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Phase 2 Recruiting

28 enrolled

Genitourinary

Penile Neoplasms

NCT05239624 2026-06-04

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05868265 2026-05-12

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Phase 2 Recruiting

24 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07087860 2026-05-08

RECIPE-B1

Phase 2 Recruiting

70 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT04878029 2026-04-29

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Phase 1 Recruiting

32 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT07110038 2026-04-16

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Phase 2 Recruiting

25 enrolled

Genitourinary

Penile Squamous Cell Carcinoma (PSCC)

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Phase 2 Recruiting

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06553885 2026-04-01

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Phase 2 Recruiting

40 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT06891560 2026-03-20

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Phase 2 Recruiting

34 enrolled

Carcinoma, Adenoid Cystic

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Phase 2 Recruiting

47 enrolled

Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

NCT07221942 2026-02-19

IMPROEV

Phase 2 Recruiting

97 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Phase 1/2 Recruiting

47 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06724159 2026-02-17

SOGUG-PRINCIS

Recruiting

500 enrolled

Genitourinary

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Phase 2 Recruiting

21 enrolled

Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

Phase 2 Recruiting

30 enrolled

Genitourinary

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

Phase 2 Recruiting

20 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06906822 2025-09-18

PlugIN

Phase 2 Recruiting

60 enrolled

Dermatologic

Melanoma

NCT06394570 2025-09-15

STAR-EV

Phase 1/2 Recruiting

19 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06302569 2025-09-09

REPRINT

Phase 2 Recruiting

23 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT05879653 2025-08-29

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

Phase 2 Recruiting

30 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT06356155 2025-07-29

NEPTUNE

Phase 2 Recruiting

32 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Phase 2 Recruiting

25 enrolled

Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Clinical Trials

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

RECIPE-B1

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

DEPECA-1 - A Phase II Study to Evaluate a First-line Systemic Therapy With Enfortumab Vedotin Plus Avelumab for Advanced and Metastatic Penile Carcinoma

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

IMPROEV

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

SOGUG-PRINCIS

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

Circulating Tumor DNA Response In Urothelial Cancer

Renal Retention in High Grade Upper Tract Urothelial Cancer

PlugIN

STAR-EV

REPRINT

Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)

NEPTUNE

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology